© 2021 MJH Life Sciences and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
© 2021 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
A panel of oncologists, patients, and a patient advocate discuss the emergence of comprehensive molecular testing in lung and thyroid cancer and consider how results can be used to inform treatment, as was done in 2 real-world cases highlighted.
June 2nd 2021
Benjamin Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, describes how molecular testing in non–small cell lung cancer has advanced and impacted treatment.
Lori J. Wirth, MD, of Massachusetts General Hospital, comments on the role of molecular testing to guide treatment decisions in thyroid cancer and explains how personalized medicine differs from standard treatment approaches.
June 9th 2021
Drs Benjamin Levy and Lori J. Wirth describe how they currently utilize comprehensive genomic profiling to manage patients with non–small cell lung cancer or thyroid cancer.
Recommendations for selecting appropriate patients for comprehensive genomic profiling and navigating through the testing process.
June 16th 2021
Drs Benjamin Levy and Lori J. Wirth comment on the current role of liquid biopsies in lung and thyroid cancer.
Common questions asked by patients with lung or thyroid cancer who have been referred for biomarker testing and advice for setting expectations from test results.
June 23rd 2021
Andrea Ferris, of the LUNGevity Foundation, explains why shared decision-making is important when recommending molecular testing to patients with lung or thyroid cancer and highlights resources provided through her organization that support patients and health care professionals.
Lori J. Wirth, MD, describes what information she looks for from results of molecular testing that help inform treatment for her patients with thyroid cancer.
June 30th 2021
Benjamin Levy, MD, briefly describes the difference between driver mutations and immunotherapy biomarkers in non–small cell lung cancer and explains how decisions for immunotherapy or targeted therapy are made based on results of molecular assays.
Drs Benjamin Levy and Lori J Wirth describe the differences between germline and somatic mutations, explain how these are detected and used to guide treatment for lung and thyroid cancer, and comment on counseling patients about concerns of hereditary findings.
A Patient With Cancer Thanks Her Brilliant Doctors and Nurses
Navigating a Daunting Cancer Landscape With an Oncology Nurse
Inside the Shifting Treatment Landscape for Advanced Genitourinary Cancers
First Patient With Lung Cancer Treated in Phase 2b Tomivosertib Trial